Blockchain Applications in the Pharmaceutical Industry

Authors

  • Mark Gaynor, PhD College of Social Justice and Public Health, Saint Louis University, St. Louis, Missouri, USA
  • Kathleen Gillespie, PhD College of Social Justice and Public Health, Saint Louis University, St. Louis, Missouri, USA
  • Allison Roe College of Social Justice and Public Health, Saint Louis University, St. Louis, Missouri, USA https://orcid.org/0009-0008-8141-6273
  • Erica Crannage, PhD Associate Professor, Pharmacy Practice, University of Health Sciences and Pharmacy, St. Louis, Missouri, USA https://orcid.org/0000-0001-8509-9609
  • J. E. Tuttle-Newhall, MD Department Chair of Surgery, East Carolina University, Greenville, North Carolina, USA

DOI:

https://doi.org/10.30953/bhty.v7.298

Keywords:

4D framework, blockchain applications, blockchain technology, clinical trials, health records, inventory systems, pharmaceutical industry, prescription misuse and abuse

Abstract

Background: In recent years, blockchain technology has made great strides in diverse industries but has fallen behind within the pharmaceutical industry. The pharmaceutical industry is complex and would benefit greatly from the distributed database and emphasis of information privacy promoted by blockchain technology. This paper identifies the potential best application for blockchain technology in the United States pharmaceutical industry by identifying current trends, companies exploring the possibilities of blockchain technology, and industry concerns with opportunities for improvement.

Methods: We utilized a 4D framework using ease of implementation, novelty, necessity, and fit of the overall industry to examine the adoption of blockchain technology in the pharmaceutical industry. Based on the 2D framework of difficulty and novelty as driving factors for the development of foundational technologies in the world of business by Iansiti and Lakhani in The Harvard Business Review, each application was ranked and scored for the best potential implementation. The potential applications proposed in this paper can be grouped into two main categories. The first category, management, includes best use cases such as health records, clinical trials, and inventory systems. The second category, monitoring, highlights cases such as pharmaceutical products, preventing counterfeits, optimizing supply chains, and addressing prescription misuse and abuse.Results: Each application was ranked by the four metrics in the framework, giving the greatest weight to necessity and ease of implementation. Using the highlighted methodology above, the applications for best implementation include Prescription Drug Misuse and Abuse Prevention, Prevention of Counterfeits, Clinical Trial Outcomes, and Smart Contracts.

Conclusion: Blockchain technology offers a new and promising solution to pharmaceutical industry needs. Each application of blockchain technology must fit within the framework of necessary, ease of implementation, familiarity amongst stakeholders, and fit of the overall industry to promote the most appropriate use.  By using the extended framework proposed by Iansiti and Lakhani we show that blockchain, in all these domains, shows promise to improve pharmaceutical industry performance. 

Downloads

Download data is not yet available.

References

Iansiti M, Lakhani, KR. The truth about blockchain [Internet]. The Harvard Business Review. 2017. [cited 2023 Dec 10]. Available from: https://hbr.org/2017/01/the-truth-about-blockchain

BlockchaIn: the chain of trust and its potential to transform healthcare – our point of view [Internet]. Office of the National Coordinator for Health Information; 2016 [cited 2023 Dec 10]. Available from: https://www.healthit.gov/sites/default/files/8-31-blockchain-ibm_ideation-challenge_aug8.pdf?source=post_page

Krawiec R, Housman D, White M, Filipova M, Quarre F, Barr D, et al. Blockchain: opportunities for health care [Internet]. Deloitte; 2016 [cited 2023 Dec 12]. Available from: https://www2.deloitte.com/us/en/pages/public-sector/articles/blockchain-opportunities-for-health-care.html

Gaynor M, BeLue R, Tuttle-Newhall JE, Martin M, Patejdl F, Vogt C. Blockchain and population health. J Public Health. 2022;44(4):e530–e6. https://doi.org/10.1093/pubmed/fdac028

Gaynor M, Tuttle-Newhall J, Parker J, Patel A, Tang C. Adoption of blockchain in health care. J Med Internet Res. 2020;22(9):e17423. https://doi.org/10.2196/17423

Abadi J, Brunnermeier M. Blockchain economics [Internet]. Princeton University; 2018 [cited 2023 Dec 12]. Available from: https://markus.scholar.princeton.edu/publications/blockchain-economics

Dimitrov DV. Blockchain applications for healthcare data management. Healthc Inform Res. 2019;25(1):51–6. https://doi.org/10.4258/hir.2019.25.1.51

Joshi K. US Pharmaceutical Industry statistics – by total revenue, region, value, job posting, total numbers 2023 [Internet]. [cited 2023 Dec 10] Available from: https://www.enterpriseappstoday.com/stats/us-pharmaceutical-industry-statistics.html

Pharmaceuticals – United States Statistica [Internet]. Statistica [cited 2023 Dec 10]. Available from: https://www.statista.com/outlook/hmo/pharmaceuticals/united-states

National health expenditures 2021 highlights [Internet]. Centers for Medicare & Medicaid Services; 2021 [cited 2023 Dec 12]. Available from: https://www.cms.gov/files/document/highlights.pdf

Blockchain in pharma LimeChain2023 [Internet] [cited 2023 Dec 10] Available from: https://limechain.tech/blockchain-use-cases/pharma/?cn-reloaded=1.

McCauley A. Why big pharma is betting on blockchain [Internet]. Harvard Business Review. 2020. [cited 2023 Dec 10] Available from: https://hbr.org/2020/05/why-big-pharma-is-betting-on-blockchain

CFO Insights. Getting smart about smart contracts Deloitte [Internet]. 2016. [cited 2023 Dec 10]. Available from: https://www2.deloitte.com/us/en/pages/finance/articles/cfo-insights-getting-smart-contracts.html

Jennings K. Pharma’s blockchain trials: novartis, merck test the tech popularized by bitcoin [Internet]. Forbes. 2021 [cited 2023 Dec 12]. Available from: https://www.forbes.com/sites/katiejennings/2021/02/02/pharmas-blockchain-trials-novartis-merck-test-the-tech-popularized-by-bitcoin/?sh=51ca767c7e86

PharmaLedger Team. Introduction to ePI by pharmaledger: more than just a PDF on your phone [Internet]. 2023 [cited 2024 Jan 17]. Available from: https://pharmaledger.org/2023/04/introduction-to-epi-by-pharmaledger-more-than-just-a-pdf-on-your-phone/

Chenthara S, Wang H, Ahmed K, Whittaker F, Ji K, A blockchain based model for curbing doctors shopping and ensuring provenance management. 2020 International Conference on Networking and Network Applications (NaNA), Haikou City, China, 10–13 December 2020; pp. 186–192.

U.S. Food and Drug Administration. Recalls [Internet]. FDA; 2024 [cited 2024 Jan 17]. Available from: https://datadashboard.fda.gov/ora/cd/recalls.htm

Pennic F. FDA okays healthcare blockchain pilot to track specialty drugs. HIT Infrastructure; 2019. https://doi.org/10.1109/NaNA51271.2020.00040

Fox A. Mayo Clinic to use blockchain for hypertension clinical trial [Internet]. Healthcare IT News. 2022 [cited 2023 Dec 12]. Available from: https://www.healthcareitnews.com/news/mayo-clinic-use-blockchain-hypertension-clinical-trial

Gupta SK. Paperless clinical trials: myth or reality? Indian J Pharmacol. 2015;47(4):349–53. https://doi.org/10.4103/0253-7613.161247

Molteni M. These DNA startups want to put all of you on the blockchain [Internet]. WIRED. 2018 [cited 2023 Dec 12]. Available from: https://www.wired.com/story/these-dna-startups-want-to-put-all-of-you-on-the-blockchain/

Dhillon V, Bass J, Hooper M, Metcalf D, Cahana A. Blockchain in healthcare: innovations that empower patients, connect professionals and improve care. Productivity Press; 2021.

Gaynor M, Lenert L, Wilson KD, Bradner S. Why common carrier and network neutrality principles apply to the Nationwide Health Information Network (NWHIN). J Am Med Inform Assoc. 2014;21(1):2–7. https://doi.org/10.1136/amiajnl-2013-001719

Gaynor M, Lenert L, Wilson K, Bradner S. It’s hard to be neutral about network neutrality for health. Health Affairs. 2014. https://doi.org/10.1377/forefront.20140818.040833

Gaynor M, Lenert L, Wilson K, Bradner S. Telecommunication policies may have unintended health care consequences. Health Affairs Blog. 2017. https://doi.org/10.1377/forefront.20170531.060342

Mendoza-Jiménez MJ, van Exel J, Brouwer W. On spillovers in economic evaluations: definition, mapping review and research agenda. Eur J Health Econ. 2024. https://doi.org/10.1007/s10198-023-01658-8

Patton T, Revill P, Sculpher M, Borquez A. Using economic evaluation to inform responses to the opioid epidemic in the United States: challenges and suggestions for future research. Subst Use Misuse. 2022;57(5):815–21. https://doi.org/10.1080/10826084.2022.2026969

Published

2024-04-18

How to Cite

Gaynor, M., Gillespie, K. ., Roe, A. ., Crannage, E. ., & Tuttle-Newhall, J. . (2024). Blockchain Applications in the Pharmaceutical Industry. Blockchain in Healthcare Today, 7(1). https://doi.org/10.30953/bhty.v7.298